Lupin has launched Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Desoximetasone Topical Spray, 0.25% had annual sales of around $18.7 million in the US (IQVIA MAT May 2018).
Lupin's Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
